Insulet Corporation (PODD)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$147.48-2.06%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · PODD
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 8.0% |
| Our one-year growth estimate | diamond | 17.1% |
Growth built into the price is above our model estimate.
The price assumes 9.2 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Model as of 2026-09-04 · Compared with 87 industry peers · Company calendar date is not available
PODD — President transition
Dated 2026-06-25
Class II director — Jonathan J. Mazelsky: Appointment of Jonathan J. Mazelsky as a Class II director, effective July 1, 2026.
Why it matters: The correction could affect customer trust and sales if not managed well.
Worry ifNo big rise in customer complaints or bad events linked to the fix.
Less concerning ifMore customer complaints or reports of bad events tied to the affected Pods.
Why it matters: Good results could boost trust in Insulet's closed-loop system. This might increase future sales.
Supportive ifThere was an announcement of good results from the EVOLVE pivotal study.
Worry ifThere was an announcement of bad results from the EVOLVE pivotal study.
Why it matters: Good trial results would back Insulet's innovation plan. This could boost future sales.
Supportive ifAnnouncement of good trial results for Omnipod 6.
Worry ifAnnouncement of bad trial results for Omnipod 6.
Why it matters: Expanding the share buyback program may show trust in the company's future.
Supportive ifInsulet says it will increase the share repurchase program.
Worry ifInsulet stops or cuts back the share repurchase program.
Why it matters: The correction affects specific lots of Omnipod products. It could impact sales and reputation.
Worry ifInsulet reports no more bad events with the affected Pods next quarter.
Less concerning ifNew reports of serious bad events linked to the affected Pods are announced.
Why it matters: Maintaining gross margin is key for profitability. A drop below this level could indicate rising costs or pricing pressure.
Worry ifGross margin reported below 71% in the upcoming quarter.
Less concerning ifGross margin remains at or above 71%.
Why it matters: Keeping margin expansion is key for making money. A drop may show operational issues.
Worry ifAdjusted operating margin grows less than 100 basis points compared to last year.
Less concerning ifAdjusted operating margin expands by 100 basis points or more year over year.
Why it matters: More share repurchases can show that management believes in the company's value. This can help the share price.
Supportive ifThere was an announcement of more share repurchases beyond the current $475 million limit.
Worry ifNo new share repurchase announcements or a pause in repurchases.
Why it matters: The company raised its revenue outlook after strong Q1 results. This signals continued growth momentum.
Supportive ifQ2 2026 revenue growth guidance above 20% in constant currency.
Worry ifQ2 2026 revenue growth guidance below 20% in constant currency.
Why it matters: Keeping a gross margin over 71% is important. This helps with profits as costs rise.
Worry ifGross margin stays above 71% in the next financial reports.
Less concerning ifGross margin falls below 71% in upcoming financial reports.
Why it matters: Ongoing legal issues may affect product supply and the company's image. Bad results can cause money and operation problems.
Worry ifIf Insulet wins the legal case, they can keep selling their products.
Less concerning ifA bad ruling or more legal problems could hurt Omnipod products.
Why it matters: Fixing this issue is important for customer trust. It also affects user safety.
Worry ifThe Medical Device Correction is fixed. There are no new reports of problems.
Less concerning ifThere are new reports of problems with the Medical Device Correction.
Why it matters: This correction may hurt customer trust and sales of Omnipod products.
Worry ifCustomer complaints or returns about the affected Omnipod lots rise a lot.
Less concerning ifCustomer feedback is good. There are no big complaints about the affected lots.
Why it matters: This growth rate is critical for assessing Insulet's market performance. A drop below 14% may signal weakening demand.
Worry ifU.S. Omnipod revenue growth of 14% or more in Q3 2026.
Less concerning ifU.S. Omnipod revenue growth below 14% in Q3 2026.
Why it matters: Total revenue growth is a key indicator of overall business health. A drop below 17.5% may raise concerns.
Worry ifTotal revenue growth of 17.5% or more in Q3 2026.
Less concerning ifTotal revenue growth below 17.5% in Q3 2026.
Why it matters: Operating margin shows how well a company makes money. If it drops below 19.3%, costs may be going up or there may be problems.
Worry ifAdjusted operating margin of 19.3% or higher in Q3 2026.
Less concerning ifThe adjusted operating margin was less than 19.3% in Q3 2026.
Why it matters: Expanding into new markets is crucial for growth. New country launches can boost revenue and market share.
Supportive ifAnnouncement of Omnipod 5 launch in at least two new countries.
Worry ifNo new country launches for Omnipod 5 in the next quarter.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$187 on $10,000 · ±1.9% | How much price usually moves either way. |
| Bad day | $432 loss on $10,000 · 4.3% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,223 loss on $10,000 · 62.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.